This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

15 Best Stocks at Top-Performing Mutual Funds (Update1)


5. CA Technologies (CA)

Company profile: CA Technologies is one of the largest independent providers of IT management software.

Investor takeaway: Its shares are up 34% this year and have a three-year annualized return of 17%. Analysts give its shares Analysts give CA's shares two "buy"ratings, four "buy/holds," and 10 "holds," according to S&P. Institutional investors own 75% of its stock.

4. Fossil (FOSL)

Company profile: Fossil, with a market cap of $7.4 billion, makes wristwatches under the Fossil, Relic and Zodiac brand names, and also produces a complementary line of belts, purses, sunglasses, and jewelry, products that are sold worldwide.

Investor takeaway: Fossil shares are up 46% this year, and have a three-year annualized return of 104%. S&P has its shares rated "buy," with a $125 price target, a 6% premium to the current price. Other analysts give its shares five "buy" ratings, five "buy/holds," and five "holds."

3. Illumina (ILMN)

Company profile: Illumina, with a $6.2 billion market value, makes equipment and consumables for genetic analysis. Its customers include academics, genome centers and pharmaceutical firms.

Investor takeaway: Its shares are up 67% this year, and have a three-year annualized return of 15.6%. Analysts give Illumina's shares six "buy" ratings, two "buy/holds," 13 "holds," and one "sell," according to S&P. Mutual funds own almost 50% of its shares.

2. Regeneron Pharmaceuticals (REGN)

Company profile: Regeneron Pharmaceuticals, with a market value of $9.8 billion, develops products that fight inflammation, cancer and eye disease. Regeneron said recently, that it expects 2012 sales for its flagship product Eylea, which treats macular degeneration, to be in the range of $250 million to $300 million, up from a prior forecast range of $140 million to $160 million. In the fourth quarter 2011, Regeneron said its loss widened to $53.4 million, or 58 cents per share, from $14.6 million, or 17 cents per share, a year earlier.

Investor takeaway: Its shares are up 80% this year, and have a three-year annualized return of 76%. Analysts give its shares eight "buy" ratings, one "buy/hold," six "holds," and one "weak hold," according to S&P.

1. Cobalt International Energy (CIE)

Company profile: Cobalt International Energy, with a $12 billion market value, is an independent, oil-focused exploration and production company.

Investor takeaway: Its shares are up 105% this year and 115% since it went public about a year ago. Analysts give its shares five "buy" ratings, four "buy/holds," and two "holds," according to S&P.

>>To see these stocks in action, visit the 15 Best Stocks at Top-Performing Mutual Funds portfolio on Stockpickr.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
4 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs